Targeting one‐carbon metabolism for cancer immunotherapy
Open Access
- 27 January 2024
- journal article
- review article
- Published by Wiley in Clinical and Translational Medicine
- Vol. 14 (1) , e1521
Abstract
Background: One‐carbon (1C) metabolism is a metabolic network that plays essential roles in biological reactions. In 1C metabolism, a series of nutrients are used to fuel metabolic pathways, including nucleotide metabolism, amino acid metabolism, cellular redox defence and epigenetic maintenance. At present, 1C metabolism is considered the hallmark of cancer. The 1C units obtained from the metabolic pathways increase the proliferation rate of cancer cells. In addition, anticancer drugs, such as methotrexate, which target 1C metabolism, have long been used in the clinic. In terms of immunotherapy, 1C metabolism has been used to explore biomarkers connected with immunotherapy response and immune‐related adverse events in patients.Methods: We collected numerous literatures to explain the roles of one‐carbon metabolism in cancer immunotherapy.Results: In this review, we focus on the important pathways in 1C metabolism and the function of 1C metabolism enzymes in cancer immunotherapy. Then, we summarise the inhibitors acting on 1C metabolism and their potential application on cancer immunotherapy. Finally, we provide a viewpoint and conclusion regarding the opportunities and challenges of targeting 1C metabolism for cancer immunotherapy in clinical practicability in the future.Conclusion: Targeting one‐carbon metabolism is useful for cancer immunotherapy.Keywords
Funding Information
- National Natural Science Foundation of China (82302918 82273287 U20A20382 82103199)
- Natural Science Foundation of Zhejiang Province (LY21H160049)
- Key Research and Development Program of Zhejiang Province (2021C03081)
This publication has 210 references indexed in Scilit:
- Increased plasma S-adenosyl-homocysteine levels induce the proliferation and migration of VSMCs through an oxidative stress-ERK1/2 pathway in apoE−/− miceCardiovascular Research, 2012
- Antroquinonol inhibits NSCLC proliferation by altering PI3K/mTOR proteins and miRNA expression profilesMutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2011
- Efficacy of S-adenosylhomocysteine hydrolase inhibitors, D-eritadenine and (S)-DHPA, against the growth of Cryptosporidium parvum in vitroExperimental Parasitology, 2010
- Ribavirin as an anti-cancer therapy: acute myeloid leukemia and beyond?Leukemia & Lymphoma, 2010
- S-adenosylhomocysteine hydrolase inhibition by 3-deazaneplanocin A analogues induces anti-cancer effects in breast cancer cell lines and synergy with both histone deacetylase and HER2 inhibitionBreast Cancer Research and Treatment, 2010
- Crystal structures of Mycobacterium tuberculosis S‐adenosyl‐L‐homocysteine hydrolase in ternary complex with substrate and inhibitorsProtein Science, 2008
- Inhibition of 5,10-methenyltetrahydrofolate synthetaseArchives of Biochemistry and Biophysics, 2007
- New agents for treatment of advanced transitional cell carcinomaAnnals of Oncology, 2006
- Phase I Study of OSI-7904L, a Novel Liposomal Thymidylate Synthase Inhibitor in Patients with Refractory Solid TumorsClinical Cancer Research, 2005
- ZD1694 (Tomudex): A new thymidylate synthase inhibitor with activity in colorectal cancerEuropean Journal of Cancer, 1995